SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Organovo Holdings, Inc. – ‘10-Q’ for 6/30/13 – ‘R22’

On:  Friday, 8/9/13, at 5:20pm ET   ·   For:  6/30/13   ·   Accession #:  1193125-13-329393   ·   File #:  1-35996

Previous ‘10-Q’:  ‘10-Q’ on 11/14/12 for 9/30/12   ·   Next:  ‘10-Q’ on 11/8/13 for 9/30/13   ·   Latest:  ‘10-Q’ on 2/8/24 for 12/31/23

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/09/13  Organovo Holdings, Inc.           10-Q        6/30/13   79:9.3M                                   Donnelley … Solutions/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    413K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     29K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     29K 
 4: EX-32.1     Exhiibt 32.1                                        HTML     23K 
77: R1          Document and Entity Information                     HTML     42K 
48: R2          Condensed Consolidated Balance Sheets               HTML    104K 
44: R3          Condensed Consolidated Balance Sheets               HTML     34K 
                (Parenthetical)                                                  
14: R4          Condensed Consolidated Statements of Operations     HTML     75K 
                (Unaudited)                                                      
47: R5          Condensed Consolidated Statements of Stockholders'  HTML    125K 
                Equity (Deficit) (Unaudited)                                     
28: R6          Condensed Consolidated Statements of Cash Flows     HTML    128K 
                (Unaudited)                                                      
65: R7          Condensed Consolidated Statements of Cash Flows     HTML     45K 
                (Unaudited) (Parenthetical)                                      
29: R8          Change in Fiscal Year End                           HTML     25K 
34: R9          Description of Business and Summary of Significant  HTML     94K 
                Accounting Policies                                              
15: R10         Derivative Liability                                HTML     46K 
31: R11         Stockholders' Equity                                HTML     96K 
64: R12         Commitments and Contingencies                       HTML     44K 
59: R13         Concentrations                                      HTML     28K 
45: R14         Subsequent Events                                   HTML     33K 
72: R15         Description of Business and Summary of Significant  HTML    170K 
                Accounting Policies (Policies)                                   
62: R16         Description of Business and Summary of Significant  HTML     48K 
                Accounting Policies (Tables)                                     
13: R17         Derivative Liability (Tables)                       HTML     38K 
18: R18         Stockholders' Equity (Tables)                       HTML     86K 
71: R19         Commitments and Contingencies (Tables)              HTML     30K 
76: R20         Description of Business and Summary of Significant  HTML     33K 
                Accounting Policies (Details)                                    
78: R21         Description of Business and Summary of Significant  HTML     38K 
                Accounting Policies (Details 1)                                  
74: R22         Description of Business and Summary of Significant  HTML    240K 
                Accounting Policies (Details Textual)                            
56: R23         Derivative Liability (Details)                      HTML     36K 
16: R24         Derivative Liability (Details Textual)              HTML     44K 
27: R25         Stockholders' Equity (Details)                      HTML     34K 
22: R26         Stockholders' Equity (Details 1)                    HTML     58K 
21: R27         Stockholders' Equity (Details 2)                    HTML     36K 
35: R28         Stockholders' Equity (Details 3)                    HTML     50K 
55: R29         Stockholders' Equity (Details 4)                    HTML     27K 
61: R30         Stockholders' Equity (Details Textual)              HTML    273K 
24: R31         Commitments and Contingencies (Details)             HTML     35K 
36: R32         Commitments and Contingencies (Details Textual)     HTML     31K 
68: R33         Subsequent Events (Details Textual)                 HTML     66K 
43: XML         IDEA XML File -- Filing Summary                      XML     90K 
79: XML.R1      Document and Entity Information                      XML    121K 
33: XML.R2      Condensed Consolidated Balance Sheets                XML    279K 
54: XML.R3      Condensed Consolidated Balance Sheets                XML     89K 
                (Parenthetical)                                                  
42: XML.R4      Condensed Consolidated Statements of Operations      XML    294K 
                (Unaudited)                                                      
39: XML.R5      Condensed Consolidated Statements of Stockholders'   XML   1.71M 
                Equity (Deficit) (Unaudited)                                     
12: XML.R6      Condensed Consolidated Statements of Cash Flows      XML    504K 
                (Unaudited)                                                      
49: XML.R7      Condensed Consolidated Statements of Cash Flows      XML    142K 
                (Unaudited) (Parenthetical)                                      
11: XML.R8      Change in Fiscal Year End                            XML     40K 
25: XML.R9      Description of Business and Summary of Significant   XML    102K 
                Accounting Policies                                              
38: XML.R10     Derivative Liability                                 XML     58K 
30: XML.R11     Stockholders' Equity                                 XML    115K 
26: XML.R12     Commitments and Contingencies                        XML     54K 
66: XML.R13     Concentrations                                       XML     41K 
32: XML.R14     Subsequent Events                                    XML     44K 
75: XML.R15     Description of Business and Summary of Significant   XML    266K 
                Accounting Policies (Policies)                                   
51: XML.R16     Description of Business and Summary of Significant   XML     70K 
                Accounting Policies (Tables)                                     
50: XML.R17     Derivative Liability (Tables)                        XML     53K 
53: XML.R18     Stockholders' Equity (Tables)                        XML    127K 
23: XML.R19     Commitments and Contingencies (Tables)               XML     45K 
46: XML.R20     Description of Business and Summary of Significant   XML    304K 
                Accounting Policies (Details)                                    
60: XML.R21     Description of Business and Summary of Significant   XML    187K 
                Accounting Policies (Details 1)                                  
63: XML.R22     Description of Business and Summary of Significant   XML   4.68M 
                Accounting Policies (Details Textual)                            
67: XML.R23     Derivative Liability (Details)                       XML    155K 
37: XML.R24     Derivative Liability (Details Textual)               XML    258K 
20: XML.R25     Stockholders' Equity (Details)                       XML    101K 
69: XML.R26     Stockholders' Equity (Details 1)                     XML    221K 
52: XML.R27     Stockholders' Equity (Details 2)                     XML     90K 
70: XML.R28     Stockholders' Equity (Details 3)                     XML    297K 
17: XML.R29     Stockholders' Equity (Details 4)                     XML    124K 
58: XML.R30     Stockholders' Equity (Details Textual)               XML   6.50M 
57: XML.R31     Commitments and Contingencies (Details)              XML     73K 
19: XML.R32     Commitments and Contingencies (Details Textual)      XML     94K 
73: XML.R33     Subsequent Events (Details Textual)                  XML    658K 
40: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS    716K 
 5: EX-101.INS  XBRL Instance -- onvo-20130630                       XML    957K 
 7: EX-101.CAL  XBRL Calculations -- onvo-20130630_cal               XML    139K 
 8: EX-101.DEF  XBRL Definitions -- onvo-20130630_def                XML    436K 
 9: EX-101.LAB  XBRL Labels -- onvo-20130630_lab                     XML    990K 
10: EX-101.PRE  XBRL Presentations -- onvo-20130630_pre              XML    714K 
 6: EX-101.SCH  XBRL Schema -- onvo-20130630                         XSD    147K 
41: ZIP         XBRL Zipped Folder -- 0001193125-13-329393-xbrl      Zip    118K

‘R22’   —   Description of Business and Summary of Significant Accounting Policies (Details Textual)

This is an IDEA Financial Report.  [ Alternative Formats ]

 
v2.4.0.8
Description of Business and Summary of Significant Accounting Policies (Details Textual) (USD $)
 1 Months Ended 3 Months Ended 12 Months Ended 74 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 74 Months Ended 3 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended 37 Months Ended 74 Months Ended
Subsequent Event [Member]
Subsequent Event [Member]
Subsequent Event [Member]
Research and Development Services [Member]
Research and Development Services [Member]
Research and Development Services [Member]
Research and Development Services [Member]
12 month research contract agreement [Member]
12 month research contract agreement [Member]
Common Stock [Member]
Maximum [Member]
Minimum [Member]
Convertible Notes Payable [Member]
2012 Equity Incentive Plan [Member]
Merger transition [Member]
Merger transition [Member]
Merger transition [Member]
Merger transition [Member]
Private_Placement
Outstanding Principal Assumed on Acquisition [Member]
Accrued Interest Assumed on Acquisition [Member]
U.S. Treasury [Member]
U.S. Treasury [Member]
Grants
NHLBI [Member]
NHLBI [Member]
NHLBI [Member]
Grants
NHLBI [Member]
Description Of Business And Summary Of Significant Accounting Policies (Textual) [Abstract]                                                                        
Number of private placement transactions                                                       3                
Total gross proceeds of approximately   $ 6,900,000 $ 1,800,000 $ 5,000,000                                         $ 6,900,000 $ 1,800,000 $ 5,000,000                  
Convertible notes, interest rate                                             6.00%                          
Convertible notes converted into shares of common stock                                                         1,500,000 25,387            
Issuance of common stock                                               6,553,986                        
Number of additional private placement transactions                                                       2                
Maturity of highly liquid investment                                         90 days                              
Useful life of fixed assets, range                                         5 years 2 years                            
Term of research contract agreement with third party                                   12 months                                    
Revenue related to research contract                             94,000 259,000                                        
Total revenue recognized from inception on the contract         106,000   259,000   3,169,000           1,313,000       600,000                                  
Research and development services on a fixed-fee basis                           1,365,000       600,000                                    
Initial payment to the Company from Agreement                           239,000                                            
Remaining payments expected to occur over                           21 months                                            
Grants         12,000       955,000                                           397,000   12,000 0 558,000 558,000
Deferred revenue related to its collaborative research programs         28,000 53,000     28,000           36,000   62,000                                      
Number of grants issued                                                               2     3  
Redemption to affected warrant holders         2,400,000                                                              
Five-year warrants to purchase shares, exercise price per share 1.00             1.00                       1.00 3.24 0.85                            
Net proceeds to company from offering                     43,300,000 43,300,000                                                
Sale of common stock in a public offering                       1,035,000                                                
Redemption price of common stock issuable         $ 0.0001                                                              
Warrant reclassified as equity instruments         23,000,000                                                              
Maximum extended period remaining for payment of additional research and development services                             28 months                                          
Description of Business and Summary of Significant Accounting Policies (Additional Textual) [Abstract]                                                                        
Conversion ratio into common stock on merger       0.0001                                                                
Common stock, par value       $ 0.001 $ 0.001 $ 0.001     $ 0.001 $ 0.0001     $ 0.001                                              
Other than common stock business acquisition conversion ratio       0.0001                                                                
Former security holders common stock voting interest         75.00%                                                              
Company's stockholders retained voting interest         25.00%                                                              
Proceeds from issuance of convertible notes payable       1,500,000         4,630,000                                                      
Accrued interest       25,387         485,000                                                      
Cash transaction costs related to the Merger approximately         2,100,000                                                              
Equity Incentive Plan, shares         896,256       896,256                                                      
Stock Issued During Period, Shares, Share-based Compensation, Gross         7,450,242       7,450,242                                                      
Accumulated deficit         70,136,000 66,365,000     70,136,000                                                      
Outstanding warrants to purchase               14,500,000                                                        
Exercise price of warrant Amended 0.80             0.80                                                        
Warrant Tender Offer               9,600,000                                                        
Aggregate proceeds of Warrants tendered 7,700,000               32,743,000     609,000                                                
Redemption price of common stock issuable         $ 0.0001                                                              
Total common stock equivalents         8,700,000   25,900,000                                                          
Cash flow from operations         (2,663,000)   (1,861,000)   (18,441,000)                                                      
Expiration date of Warrant Tender Offer         Dec. 21, 2012                                                              
Additional proceeds from exercise of warrants           1,400,000                                                            
Restricted Cash         38,300 88,300     38,300                                                      
Restricted cash 38,300             38,300                                                        
Additional restricted cash           50,000                                                            
Inventory of raw materials         85,000 88,000     85,000                                                      
Obsolete inventory reserve         0 0     0                                                      
Impairment of long-lived assets                 0                                                      
Estimated useful life of the fixed assets         The estimated useful life of the fixed assets range between two and five years.                                                              
Dilutive effect         $ 0.00   $ 0.00                                                          
Fee for additional research and development services         135,000                                                              
Total contract value         1,500,000                                                              
Total stock reserved for future issuance         9,316,582       9,316,582                                                      
Recognized expenses of warrants               1,900,000                                                        
Proceeds received from exercise of warrants               $ 400,000                                                        

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
8/31/13
Filed on:8/9/13
8/2/13424B5,  8-K
For Period end:6/30/13
3/31/1310-KT,  8-K
3/14/134
12/31/1210-K
12/21/124,  8-K
6/30/1210-Q
3/16/123,  4,  4/A,  8-K
2/29/128-K,  D/A
2/8/128-K,  8-K/A
2/7/12D
10/31/1110-Q
12/31/10
 List all Filings 
↑Top
Filing Submission 0001193125-13-329393   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Tue., Apr. 30, 4:52:00.1am ET